BioStock: Medivir’s phase Ib/IIa study successfully concluded

Medivir has announced the conclusion of its phase Ib/IIa study evaluating fostrox in combination with Lenvima for second- or third-line treatment of advanced liver cancer. The remaining patients have been transitioned to a compassionate use program, ensuring continued treatment access.
– We are very satisfied that the remaining three patients can now transition to a compassionate use solution, enabling them to continue benefit from fostrox and maintain control over their liver cancer, says Jens Lindberg, CEO of Medivir.

Read the article at biostock.se:

https://www.biostock.se/en/2024/11/medivirs-phase-ib-iia-study-successfully-concluded/

This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se/